哮喘患者血清和支气管肺泡灌洗液中白细胞介素12水平检测及意义

摘要

Objective To observe the concentration changes of serum and bronchoalveolar lavage fluid interleukin-l2(IL-12) in acute exacerbations of asthmatic patients before and after treatment,and evaluate its influence on asthma.Methods Enzyme-linked immunosorbent assay(ELISA) was used to detect the concentration of IL-12 in BALF and serum of observed group and control group,including 58 patients with acute asthma attack (observed group) before and after treatment, 30 healthy and non-smoking voluntary blood donors for the serum control group and 12 healthy subjects, whose chief complaint was chest pain, for the BALF control group.Results Serum and BALF concentrations of IL-12 in asthma acute attack group were significantly lower than those of remission stages(after treatment) and healthy control group( P ＜0.05).While, the concentrations of serum and BALF IL-12 in remission stages were not significantly decreased than those of healthy control group( P ＞0.05).Conclusion Asthmatic patients with acute asthma attack have lower ability of releasing IL-12,and they are unable to inhibit the synthesis and the release of inflammation or pro-inflammatory, which may be involved in the pathogenesis of asthma.There is some clinical value to determine the dynamic changes of IL-12 concentration in patients with asthma.%目的 观察急性期哮喘患者治疗前后血清和支气管肺泡灌洗液(BALF)中白细胞介素12(IL-12)水平的变化,研究其与疾病的关系.方法 使用酶联免疫吸附测定(ELISA)法检测58例急性期哮喘患者(试验组)治疗前、后IL-12水平;健康非吸烟的自愿献血者30例,为血清对照组,检测其血清IL-12的水平;以胸痛为主诉进行BALF检查证实为健康者12例,作为BALF对照组,检测其IL-12水平的水平.结果 急性期哮喘患者血清和BALF中IL-12水平明显低于缓解期(治疗后)和健康对照组(P0.05).结论 提示急性期哮喘患者IL-12分泌减少,不能有效抑制炎症或促炎症细胞因子的合成及释放,亦即不能有效抑制炎症反应,可能是导致或加重气道炎症的原因之一.动态测定IL-12水平是判断支气管哮喘病情变化的有益指标.